Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17594551 | 0.89 | TP53 (0.44) | ESR2ESR1MAOBLMNATP53 | |
| SCHEMBL24239390 | 0.89 | TP53 (0.44) | ESR2ESR1MAOBLMNATP53 | |
| SCHEMBL10635452 | 0.83 | ESR1 (0.48) | ESR2ESR1TTRMAOBLMNA | |
| SCHEMBL27639730 | 0.82 | TP53 (0.50) | MAOBTP53 | |
| SCHEMBL13213549 | 0.79 | ESR1 (0.47) | ESR2ESR1TTRLMNATP53 | |
| SCHEMBL19003837 | 0.79 | ESR1 (0.47) | ESR2ESR1TTRLMNATP53 | |
| SCHEMBL28685553 | 0.77 | ROCK2 (0.48) | LMNATP53 | |
| SCHEMBL31277829 | 0.77 | ROCK2 (0.48) | LMNATP53 | |
| SCHEMBL29052819 | 0.75 | TP53 (0.51) | LMNATP53 | |
| SCHEMBL26970911 | 0.75 | TP53 (0.51) | LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146896-A1 | BICYCLIC-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| CN-1863799-B | Chromancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | SK CORP | 2010-09-22 | — | — | CN | disclosed |
| US-7446127-B2 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | SK HOLDINGS CO, LTD. (KR) | 2008-11-04 | — | — | US | disclosed |
| US-7446127-B2 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | SK HOLDINGS CO, LTD. (KR) | 2008-11-04 | — | — | US | disclosed |
| US-7446127-B2 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | SK HOLDINGS CO, LTD. (KR) | 2008-11-04 | — | — | US | disclosed |
| CN-1863799-A | Chromancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | SK CORP (KR) | 2006-11-15 | — | — | CN | disclosed |
| EP-1660490-A1 | CHROMAN CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | SK Corporation (KR) | 2006-05-31 | — | — | EP | disclosed |
| US-20050107371-A1 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2005-05-19 | — | — | US | disclosed |
| WO-2005021540-A1 | CHROMAN CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | SK CORPORATION (KR) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107371-A1 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | GPR119, CEL, ACACA | ESR2 1385/4885ESR1 2364/4885TTR 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.